Results 51 to 60 of about 5,436,787 (348)

The Challenges and Opportunities of lncRNAs in Ovarian Cancer Research and Clinical Use [PDF]

, 2020
[Abstract] Ovarian cancer is one of the most lethal gynecological malignancies worldwide because it tends to be detected late, when the disease has already spread, and prognosis is poor.
Barreiro-Alonso, Aida, Cerdán, María Esperanza, Lamas, Mónica, Quindós-Varela, María, Rodríguez-Belmonte, Esther, Salamini-Montemurri, Martín, Vizoso-Vázquez, Ángel   +6 more
core   +1 more source

The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation

Nucleic Acids Research, 2020
N 6-Methyladenosine (m6A) is the most abundant RNA modification in mammal mRNAs and increasing evidence suggests the key roles of m6A in human tumorigenesis.
Tao Liu, Qinglv Wei, Jing Jin, Qingya Luo, Yi Liu, Yu Yang, Chunming Cheng, Lanfang Li, Jingnan Pi, Yanmin Si, Hualiang Xiao, Li Li, Shuan Rao, Fang Wang, Jianhua Yu, Jia Yu, D. Zou, P. Yi   +17 more
semanticscholar   +1 more source

Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions

Nature Communications, 2019
OPCML is a tumour suppressor gene that is epigenetically silenced in ovarian cancer and is somatically mutated in various cancers. Here, the authors solve the X-ray crystal structure of OPCML and model clinically relevant mutations that could contribute ...
James R. Birtley, Mohammad Alomary, Elisa Zanini, Jane Antony, Zachary Maben, Grant C. Weaver, Claudia Von Arx, Manuela Mura, Aline T. Marinho, Haonan Lu, Eloise V. N. Morecroft, Evdoxia Karali, Naomi E. Chayen, Edward W. Tate, Mollie Jurewicz, Lawrence J. Stern, Chiara Recchi, Hani Gabra   +17 more
doaj   +1 more source

Exosomes promote pre-metastatic niche formation in ovarian cancer. [PDF]

, 2019
Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Dean, Dylan C, Duan, Zhenfeng, Feng, Wenlong, Hornicek, Francis J, Shi, Huirong   +4 more
core   +2 more sources

Treatment of epithelial ovarian cancer

British medical journal, 2020
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highest mortality rate among these cancers. A stepwise approach to assessment, diagnosis, and treatment is vital to appropriate management of this disease ...
L. Kuroki, S. Guntupalli
semanticscholar   +1 more source

The accurate staging of ovarian cancer using 3T magnetic resonance imaging - a realistic option [PDF]

, 2008
Objectives: The aim of the study was to determine whether staging primary ovarian cancer using 3.0 Tesla (3T) magnetic resonance imaging (MRI) is comparable to surgical staging of the disease.
Booth, SJ, Poole, DR, Richmond, I, Turnbull, LW   +3 more
core   +1 more source

Drug resistance in ovarian cancer: from mechanism to clinical trial

Molecular Cancer
Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian ...
Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang, Dongling Zou   +10 more
semanticscholar   +1 more source

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca, 2019
Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. The outcomes are complicated, because the disease is often diagnosed late and composed of several subtypes with distinct biological and molecular ...
S. Lheureux, Marsela Braunstein, A. Oza
semanticscholar   +1 more source

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi, A Mai, A Saito, A Vannini, A Villar-Garea, AA Lane, AJ Dembo, AJ Wilson, Albandri Alfraidi, AM Abukhdeir, Aun Muhammad, AW Kurian, B Sorbe, BA Goff, BD Strahl, BH Huang, BY Karlan, C Aghajanian, C Bosetti, C Campas-Moya, C Gomez-Raposo, CJ Dunton, CM Grozinger, CS Marcus, CT Lin, D Khabele, D Matei, D Mottet, D Strumberg, D Waltregny, DC Drummond, DD Bowtell, DE Marsden, DK Armstrong, DM Dinulescu, Dmitri Pchejetski, DO Bauerschlag, E Hu, E Smolle, E Verdin, G Piperno, G Tortolero-Luna, H Naora, HA Risch, Heba Alshaker, HL Cheng, I Cetin, IK Kolasa, J Boyd, J Morrison, J Permuth-Wey, J Plisiecka-Halasa, J Prat, J Sonnemann, J Zhang, JA Rauh-Hain, JE Bolden, JE Palmer, JF Stratton, JH Choi, JJ Hwang, JL Benedet, JL MacDonald, JL Walker, JM Piek, JP Secrist, JR Graff, JR Ribeiro, K Kudoh, K Ozaki, K Sawada, K Struhl, KA Lowe, KB Glaser, Keith Sacco, KF McGonigle, KR Cho, L Dai, Leonardo Monzon, M Booth, M Fung-Kee-Fung, M Kartalou, M Markman, M Ohmichi, M Schuijer, MF Fathalla, MJ Piccart, MJ Scanlan, MK Tuxen, ML Friedlander, MM Leitao, MS Finnin, MS Kim, N Einhorn, N Einhorn, N Takai, N Takai, N Takai, NC Hait, NG Gavalas, NS Bese, P Marks, P Zhu, PH Wang, R Furumai, RA Burger, RA Burger, RC Bast Jr, RF Ozols, RL Coleman, RP Warrell Jr, RP Wernyj, S Gregoire, S Rinaldi, S Senese, S Spiegel, SA Cannistra, SA Gayther, SA Gayther, SC Modesitt, SR Wedge, T Meyer, TJ Herzog, TJ Perren, TL Klug, V Auner, V Conteduca, W Fischle, W Weichert, X Qian, YV Shebzukhov   +130 more
core   +1 more source

CA125 and Ovarian Cancer: A Comprehensive Review

Cancers, 2020
Simple Summary CA125 has been the most promising biomarker for screening ovarian cancer; however, it still does not have an acceptable accuracy in population-based screening for ovarian cancer.
Parsa Charkhchi, C. Cybulski, J. Gronwald, F. Wong, S. Narod, M. Akbari   +5 more
semanticscholar   +1 more source